Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Citrinin (HB3839)
Description:Mitochondrial permeability transition pore (MPTP) activator
Purity:>97%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
Deschloroclozapine (DCZ) (HB8555)
Description:Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator.
Purity:>98%
(S)-3,5-DHPG (HB0045)
Description:Selective group I mGlu receptor agonist. Induces LTD.
Purity:>99%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant. Water soluble.
Purity:>98%